Robust finish to FY18; mid-term financial targets within reach
-"Vifor reported strong FY18 results with revenue as well profits exceeding the already raised targets – driven by Ferinject, Veltassa and VFMCRP. The positive growth momentum is likely to continue in ..."
You may also be interested by these reports :
Despite our lower EPS19, the target price moves slightly up driven by the higher earnings from 2020 onwards, and the higher DCF and SOTP valuations.
The high uncertainty of the final decisions on the lawsuits triggers the change of our Add to Reduce due to the vague payments. The lower valuation ...
We have clearly reduced the amount of the expected impairments for the coming years, especially in 2019, as management missed the chance to tidy up ...
The last one year has been a roller-coaster ride for the pure-play biotech, Genmab (Add, Denmark). While an R&D setback (two studies discontinued) in ...